A carregar...
Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert
Recently, the FDA issued a public safety alert, responding to results of the now-published Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) trial. CARES showed no significant difference between allopurinol and febuxostat in the primary...
Na minha lista:
| Publicado no: | Arthritis Rheumatol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6203619/ https://ncbi.nlm.nih.gov/pubmed/29869840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40583 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|